PRZOOM - /newswire/ -
Shanghai, China, 2012/12/07 - A growing realization of the risks involved during vaccination has led to the development of several new types of syringes designed to prevent re-use - AdvaCarePharma.com.

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!

It is undeniable that needles and syringes continue to be vital tools in numerous areas of healthcare and if used incorrectly, it can lead to often deadly diseases and infections. This happens most commonly with repeated needle use on multiple patients.

A study carried by the World and Health Organization (2009) showed that at least 30 percent of injections given to patients in developing countries are currently classified as being unsafe. Incorrect injection methods are a major source of transmission for several diseases, including hepatitis B and C, HIV, malaria, and viral hemorrhagic fevers and may cause abscesses and septicemia. The long term consequences of these diseases are devastating for both individuals in the developing nations and the future of the developing countries.

A growing realization of the risks involved during vaccination has led to the development of several new types of syringes designed to prevent re-use. Auto-disable or auto-disposable syringes automatically lock or break internally after one use, effectively disabling any ability to use it on multiple occasions. Both the WHO and UNICEF currently recommend the replacement of disposable syringes with auto-disable syringes when administering vaccines, especially during mass immunization programs.

In line with these findings, AdvaCare has stepped up its provision of auto-disable syringes, providing competitive pricing to help continuing the fight against the transmission of such diseases.

AdvaCare’s WHO (PQS) and USFDA-certified auto-disable syringes are sterile, non-toxic, non-phylogenic and made from high quality material. The transparent barrel allows for an accurate measurement and detection of air bubbles, making them both safe and user-friendly. Available as luer-slip or luer-lock, AdvaCare offers both types to suit the needs of individual markets. However, AdvaCare promotes the use of luer lock syringes which allow needles to be screwed onto the tip and prevent the removal of needles post-injection.

Designed based on market research and according to US standards, AdvaCare's packaging can also be customized to suit the buyer’s requirements. AdvaCare currently packages their auto-disposable syringes as 1 piece per PE bag or blister pack, 100 packs per box and 20 boxes per carton. The above packaging quantities are also customizable to suit required specifications. The auto-disable syringes are available in different capacities: 1 ml, 2 ml, 3 ml, 5 ml, 10 ml, 20 ml, 30 ml, 50 ml and 60 ml.

AdvaCare’s auto-disable syringes were featured in their newsletter campaign last month. To be placed on this newsletter’s mailing list, please submit an email address under “Newsletter” in the “Contact” section on AdvaCare Pharma’s website. This newsletter will be very beneficial to those who are interested in learning about quality products at the best prices. AdvaCare's 3 main products lines will be featured in each newsletter: Finished Pharmaceuticals, Veterinary Products and Medical Disposables. Only those that purchase through AdvaCare’s newsletter will be able to take advantage of special promotions and discounts.

PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any AdvaCare Pharma securities in any jurisdiction including any other companies listed or named in this release.